First-in-Human trial tests immune cells to fight ALS
NCT ID NCT06671236
Summary
This early-stage study is testing whether a patient's own immune cells, called regulatory T cells (Tregs), can be safely injected into the spinal fluid to potentially slow the progression of ALS. The study will enroll 12 adults with ALS to receive up to three injections over two months, followed by monitoring for safety and any effects on ALS symptoms. This is a Phase 1 trial, meaning its primary goal is to find a safe dose and understand side effects, not to prove the treatment works.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS (ALS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Zhengzhou University
RECRUITINGZhengzhou, Henan, 450052, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.